Welcome to the Genentech Medical Twitter page! This page is intended for US Healthcare Professionals only.
This Twitter page has been created by Genentech Medical Affairs as a forum to share scientific information. This includes, but is not limited to, medical information, disease education, research updates, and clinical trial information that may be investigational in nature. The information presented on the Genentech Medical Twitter page does not imply US FDA approval and should not be construed as a recommendation for use.
There are regulations in our industry that regulate what can and cannot be said on our Twitter page. As a result, all @mentions, comments, replies, pictures, and videos posted on this Twitter page will be moderated. Tweets that are offensive, threatening, or violate our Community Guidelines will not be shown on our page and may result in the user getting blocked from this Twitter page and/or reported to Twitter.
Please review and familiarize yourself with the rules below before you post any comments or replies to this Twitter page. Generally, we will respond to comments or replies to our Tweets at the earliest opportunity but will not respond to comments or replies to our Tweets that violate our Community Guidelines or Twitter Terms of Service.
Join the conversation.
We want you to be part of the community. We welcome your comments and replies on our Twitter page as long as you follow our Community Guidelines. If your comment or reply is off-topic, confusing or misleading, or violates our Community Guidelines, it will not be shown on the page.
Since we have to be mindful of the regulations that govern our industry, please do not post any comments or replies that reference Genentech products and services or those of our competitors.
Report adverse events.
If you are aware of anyone that has experienced any adverse events related to Genentech products, we encourage you to report them immediately to Genentech Drug Safety by emailing [email protected] or calling 1-888-835-2555. You can also contact the FDA directly by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. If your comment or reply includes an adverse event that anyone you are aware of has experienced while taking a Genentech product, we will follow required processes to report this adverse event to the FDA and you may be contacted with questions or for additional information.
Do not solicit or give medical advice.
This Twitter page is for informational purposes only and is not intended to replace the advice or clinical judgment of any qualified healthcare professional. Though many who follow and interact with this Twitter page are part of the healthcare community (eg, physicians, nurses, scientists), this is not a forum for giving medical advice.
Respect users’ privacy.
We want you to share this content with other US healthcare professionals, so you may include @mentions in your comments or replies. Please do not share personal information about yourself or others that is not in the public domain. Do not post comments, replies, or @mentions that include either positive or negative feedback about specific healthcare professionals, institutions, facilities, or clinics.
Be respectful of others.
This Twitter page is meant to communicate medical and clinical trial information from Genentech Medical Affairs to healthcare professionals. Please refrain from using language that is disrespectful, obscene, offensive, inflammatory, discriminatory, or that contains profanity.
User-generated content is public.
You understand and agree that user-generated content will be treated as nonconfidential and nonproprietary and that you are giving us and our affiliates a royalty-free, irrevocable, perpetual, nonexclusive, and fully sublicensable license to use, reproduce, modify, adapt, publish, translate, create derivative works from, distribute, perform, and display such user-generated content in whole or in part, on a worldwide basis, and to incorporate that content in other works, in any form, media, technology, or products now known or later developed, including for promotional or marketing purposes; and you further represent, warrant, and covenant that you have and will continue to have the legal right to grant these rights.
Any product advertisements or offers of healthcare services will not be shown on this Twitter page.
We reserve the right to update our Community Guidelines at any time. If we do make changes to our Community Guidelines, any comment or reply you post on this Twitter page indicates your acceptance of any revisions to these terms.
Visit www.gene.com/privacy-policy for more information about privacy at Genentech.
Follow the law.
Do not post comments or replies that violate copyright and/or other intellectual property law, are fraudulent or deceptive, are libelous or defamatory, or promote violence or illegal activity.
Genentech does not control and is not responsible for the accuracy of any opinions, advice, information, or other comments or replies posted on this Twitter page by third parties, including subject matter experts. The views expressed in comments or replies posted on this Twitter page are solely those of the commenters and do not necessarily represent the views of Genentech, their employees, or affiliates.
Genentech may share links to third-party sites; however, Genentech does not endorse and is not responsible for the content on those websites.
Twitter accounts that Genentech follows or is followed by are not an indication of Genentech’s endorsement of these accounts or the content they produce.
Visit www.gene.com/terms-conditions for Genentech Terms & Conditions or https://twitter.com/en/tos for Twitter Terms of Service.
Contact us.
Visit www.genentech-medinfo.com/resources.html to connect with your Medical Science Liaison (MSL), submit a medical inquiry, and participate in an online chat or video conference with a specialist.
Visit www.genentech-medinfo.com to access an online library of product and clinical information designed to foster scientific exchange.
Visit www.gene.com/medical-professionals/pipeline to learn more about Genentech research and development activities and investigational medicines.
Visit https://genentech-clinicaltrials.com for the latest updates on Genentech clinical trials and supporting research.
If warranted, Genentech may reach out to further discuss your questions offline.
The link you have selected will take you to Genentech Clinical Trials, a different site also maintained by Genentech Medical Affairs.
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
Ab: antibody
AE: adverse event
ASTCT: American Society for Transplantation and Cellular Therapy
CR: complete response
CRS: cytokine release syndrome
CT: computed tomography
CTCAE: Common Terminology Criteria for Adverse Events
DoR: duration of response
ECOG PS: Eastern Cooperative Oncology Group performance status
FL: follicular lymphoma
ICANS: immune effector cell-associated neurotoxicity syndrome
IRF: independent review facility
IV: intravenous
IQR: interquartile range
NCI CTCAE: National Center Institute Common Terminology Criteria for Adverse Events
NHL: non-Hodgkin lymphoma
ORR: objective response rate
PET: positron emission tomography
PFS: progression-free survival
PR: partial response
R/R: relapsed/refractory
SAE: serious adverse event
SD: stable disease
USPI: United States Prescribing Information
UTI: urinary tract infection
ABC: activated B-cell–like subtype
BICR: blinded independent central review
CI: confidence interval
CNS: central nervous system
CR: complete response
DLBCL: diffuse large B-cell lymphoma
ECOG PS: Eastern Cooperative Oncology Group performance status
EFSefficacy: event-free survival for efficacy causes (time from randomization to the earliest occurrence of disease progression/relapse, death due to any cause, initiation of any non-protocol specified anti-lymphoma treatment, or biopsy-confirmed residual disease after treatment completion)
EOT: end of treatment
GCB: germinal-center B-cell–like subtype
HGBL: high-grade B-cell lymphoma
HHV8: human herpesvirus 8
HR: hazard ratio
INV: investigator
IPI: International Prognostic Index
ITT: intention-to-treat
LYSA: Lymphoma Study Association
NE: not evaluable
NOS: not otherwise specified
OS: overall survival
PET-CT: positron emission tomography and computed tomography
PFS: progression-free survival
Pola-R-CHP: polatuzumab plus rituximab, cyclophosphamide, doxorubicin, prednisone
R: randomization
R-CHOP: rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone
R-CHP: rituximab plus cyclophosphamide, doxorubicin, prednisone
USPI: United States Prescribing Information
DBPCFC: Double-blind, placebo-controlled food challenge
FDA: Food and Drug Administration
ICH: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
IgE: Immunoglobulin E
NIH: National Institutes of Health
OIT: Oral immunotherapy
OLE: Open-label extension
R: Randomized
CD19: Cluster of differentiation 19
CD20: Cluster of differentiation 20
CDC: Centers for Disease Control and Prevention
COVID-19: Coronavirus disease of 2019
DMT: Disease-modifying therapy
ECTRIMS: European Committee for Treatment and Research in Multiple Sclerosis
EMA: European Medicines Association
FDA: Food and Drug Administration
IgG1: Immunoglobulin G1
LMP: Last menstrual period
mAb: Monoclonal antibody
MCA: Major congenital anomalies
MS: Multiple sclerosis
OCR: OCREVUS (ocrelizumab)
RID: Relative infant dose
UCSF: University of California San Francisco
URTI: Upper respiratory tract infection
UTI: Urinary tract infection
ASTCT: American Society for Transplantation and Cellular Therapy
CD20: Cluster of differentiation 20
CR: Complete response
CRS: Cytokine release syndrome
CT: Computed tomography
CTCAE: Common Terminology Criteria for Adverse Events
DLBCL: Diffuse large B-cell lymphoma
DoCR: Duration of complete response
DoR: Duration of response
ECOG PS: Eastern Cooperative Oncology Group performance status
FL: Follicular lymphoma
HGBCL: High-grade B-cell lymphoma
ICANS: Immune effector cell-associated neurotoxicity syndrome
IRC: Independent Review Committee
NOS: Not otherwise specified
ORR: Objective response rate
PET: Positron emission tomography
PMBCL: Primary mediastinal B-cell lymphoma
AE: Adverse event
Ang2: Angiopoietin-2
ASTCT: American Society for Transplantation and Cellular Therapy
ATG: Anti-thymocyte globulin
CAR: Chimeric antigen receptor
CARTOX: CAR T-cell Therapy-Associated Toxicity
CD3: Cluster of differentiation 3
CPAP: Continuous positive airway pressure
CRP: C-reactive protein
CRS: Cytokine release syndrome
CTCAE: Common Terminology Criteria for Adverse Events
DIC: Disseminated intravascular coagulation
HLH: Hemophagocytic lymphohistiocytosis
ICANS: Immune effector cell–associated neurotoxicity syndrome
ICU: Intensive care unit
IFN-γ: Interferon-gamma
IL: Interleukin
INR: International normalized ratio
IRR: Infusion-related reaction
MAS: Macrophage activation syndrome
MSKCC: Memorial Sloan Kettering Cancer Center
NO: Nitric oxide
PTT: Partial thromboplastin time
TNF-α: Tumor necrosis factor alpha
VWF: von Wilebrand factor
CD3: Cluster of differentiation 3
TCR: T-cell receptor
CD4: Cluster of differentiation 4
CD8: Cluster of differentiation 8
CD226: Cluster of differentiation 226
Ig: Immunoglobulin
ITIM: Immunoreceptor tyrosine-based inhibitory motif
MHC: Major histocompatibility complex
NK: Natural killer
PD-1: Programmed cell death protein 1
PD-L1: Programmed death-ligand 1
PVR: Poliovirus receptor
TIGIT: T-cell immunoreceptor with Ig and ITIM domains
ARR: Annualized Relapse Rate
ART: Assisted Reproductive Technology
CI: Confidence Interval
DMT: Disease-modifying therapy
EDSS: Expanded Disability Status Scale
MS: Multiple Sclerosis
T: Trimester
OR: Odds ratio
OB/Gyn: Obstetrics and Gynecology
AAAAI: American Academy of Allergy Asthma & Immunology
DMT: Disease-modifying therapy
HCP: Health Care Provider
Ig: Immunoglobulin
LLN: Lower limit of normal
MS: Multiple Sclerosis
NK: Natural killer
FAERS: FDA Adverse Event Reporting System
FDA: US Food and Drug Administration
Ig: Immunoglobulin
LMP: last menstrual cycle
MCA: major congenital anomalies
MS: Multiple sclerosis
OCR: OCREVUS (ocrelizumab)
PML: progressive multifocal leukoencephalopathy
PPMS: Primary progressive multiple sclerosis
RMS: Relapsing multiple sclerosis
The link you have selected will take you to a separate website not owned or controlled by Genentech. Genentech does not recommend, endorse, or make any representation regarding the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.